Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 2

ash.confex.com

Oral and Poster Abstracts Oral 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Targeted Therapies and Novel Therapies Clinical Trials, Clinical Research Eunice S. Wang, MD1, Pau Montesinos, PhD, MD2*, Mark D. Minden, MD, PhD3, Je-Hwan Lee, MD, PhD4, Michael Heuser, MD5, Tomoki...

  • 123456 Profile photo of Madelyn

    In a randomized trial in FLT3 AML ineligible for intensive chemotherapy gilteritinib + AZA did not show an OS benefit vs. AZA alone. CR rates for both arms were similar (16.2% vs 14.3%), CRc rates were significantly higher for GIL+AZA vs AZA (58.1 vs 26.5%). Significantly more patients (44 v 20%) received subsequent AML therapy in the AZA alone arm, which may help explain the lack of OS benefit despite the 31% increase in CRc with Gil.